Femme et Homme
- | Pays :
- Italy
- United States
- Germany
- ...
- | Organes : -
- | Spécialités : -
Extrait
This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST. This study is designed to determine the Phase II dose of AMN107 and imatinib when administered together in patients with imatinib-resistant GIST, and to characterize the safety, tolerability and pharmacokinetic (PK) profile of this combination.
Critère d'inclusion
- gastrointestinal stromal tumors